Abbott admits guilt in Depakote off-label case; paying $1.6bn
This article was originally published in Scrip
US drug maker Abbott pleaded guilty to misbranding its antiseizure and biopolar medicine Depakote (divalproex) by promoting it as a therapy to control agitation and aggression in elderly dementia patients and as a treatment for schizophrenia – indications not approved by the US FDA, prosecutors said on 7 May.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.